85102-99-4

Basic information

• Product Name: 1-BENZYL-1H-IMIDAZOLE-5-CARBOXALDEHYDE
• Synonyms: 3-BENZYL-3H-IMIDAZOLE-4-CARBALDEHYDE;AKOS BB-8933;1-BENZYL-1H-IMIDAZOLE-5-CARBALDEHYDE;1-BENZYL-1H-IMIDAZOLE-5-CARBOXALDEHYDE;1-BENZYLIMIDAZOLE-5-CARBALDEHYDE;ASINEX-REAG BAS 12433644;TIMTEC-BB SBB010121;1-Benzyl-1H-imidazole-5-carbox
• CAS NO: 85102-99-4
• Molecular Formula: C₁₁H₁₀N₂O
• Molecular Weight: 186.21
• Product Categories: Aldehydes;blocks;Imidazoles;Imidazoles & Benzimidazoles;Imidazoles & Benzimidazoles
• Mol File: 85102-99-4.mol
• Article Data: 17

Chemical Properties

• Melting Point: 46-49°C
• Boiling Point: 383.7 °C at 760 mmHg
• Flash Point: 185.8 °C
• Appearance: /
• Density: 1.12 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: Keep Cold
• Solubility: DCM
• PKA: 3.65±0.13(Predicted)
• CAS DataBase Reference: 1-BENZYL-1H-IMIDAZOLE-5-CARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-1H-IMIDAZOLE-5-CARBOXALDEHYDE(85102-99-4)
• EPA Substance Registry System: 1-BENZYL-1H-IMIDAZOLE-5-CARBOXALDEHYDE(85102-99-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-36-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 85102-99-4(Hazardous Substances Data)

Usage

Uses

3-Benzyl-3H-imidazole-4-carboxaldehyde is an constituent in the synthesis of Fadolmidine (F101040), a novel α2-adrenoceptor (α2-AR) agonist that exhibits antinociception properties.

InChI:InChI=1/C11H10N2O/c14-8-11-6-12-9-13(11)7-10-4-2-1-3-5-10/h1-6,8-9H,7H2

Upstream product

• 3034-50-2 5-imidazolecarboxaldehyde 
• 100-39-0 benzyl bromide 
• 100-46-9 benzylamine 
• 17674-16-7 benzyl triflate 
• 33016-47-6 (1-tritylimidazol-4-yl)carboxaldehyde 
• 100-44-7 benzyl chloride 
• 76075-21-3 ethyl 1-benzyl-1H-imidazole-5-carboxylic acid 
• 60293-41-6 N-((E)-3-phenylallylidene)benzylamine 
• 98412-23-8 1-benzyl-2-mercapto-5-hydroxymethyl-imidazole 
• 626242-04-4 (1-benzyl-1H-5-imidazolyl)methyl acetate 
• 160999-35-9 1-Benzyl-5-(2-phenylethenyl)-1H-imidazole 
• 52726-21-3 5-methyl-1-(phenylmethyl)imidazole 
• 3034-50-2 4⁽⁵⁾formylimidazole 

Downstream Products

• 86803-31-8 1-benzyl-5-vinyl-1H-imidazole 
• 80304-50-3 1-benzyl-5-hydroxymethylimidazole 
• 880106-38-7 4-[N-(1-benzyl-1H-imidazol-5-yl)methylamino]-2-phenylbenzoylmethionine methyl ester 
• 489409-09-8 C₂₅H₂₃N₃O₂ 
• 1166976-88-0 (3-benzyl-3H-imidazol-4-ylmethyl)-(3'-methyl-biphenyl-3-yl)-amine 
• 1166976-90-4 (3-benzyl-3H-imidazol-4-ylmethyl)-(2',3'-dimethyl-biphenyl-3-yl)-amine 
• 1166976-95-9 (3-benzyl-3H-imidazol-4-ylmethyl)-(3-pyridin-4-yl-phenyl)-amine 
• 1166976-94-8 (3-benzyl-3H-imidazol-4-ylmethyl)-(3-pyridin-3-yl-phenyl)-amine 
• 1166976-83-5 (3-benzyl-3H-imidazol-4-ylmethyl)-(3-isopropyl-phenyl)-amine 
• 1166976-81-3 (3-benzyl-3H-imidazol-4-ylmethyl)-biphenyl-3-yl-amine 
• 1349797-11-0 (3-benzyl-3H-imidazol-4-ylmethyl)-(2'-methyl-biphenyl-3-yl)-amine 
• 1417526-45-4 N-((1-benzyl-1H-imidazol-5-yl)methyl)-N-ethylethanamine 

Relevant articles and documents

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.

Structurally simple inhibitors of lanosterol 14α-demethylase are efficacious in a rodent model of acute Chagas disease

We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14α-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T. cruzi amastigotes in vitro with values of EC 50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.

Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3H- cycloheptimidazol-4-ones and 2-alkyl-3H-cycloheptimidazol-4-ones

Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3H- cycloheptimidazol-4-one (1) and 2-alkyl-3H-cycloheptimidazol-4-one (2) was investigated. 3-[2′-(1-tert-Butyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2- propyl-5,6,7,8-tetrahydro-1H-cycloheptimidazol-4-one (6) was preferentially obtained under the conditions by using NaH in DMF or THF. On the other hand, 3-[2′-(1-tert-butyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2-propyl-5,6,7, 8-tetrahydro-3H-cycloheptimidazol-4-one (5), the synthetic intermediate compound of Pratosartan, was obtained selectively in the presence of n-Bu4NBr in toluene by using aqueous sodium hydroxide as a base. In this reaction, it was found that the concentration of the alkaline solution influences its regioselectivity. This selectivity was observed even for aldehyde and ester derivatives.